about
New options with dabigatran etexilate in anticoagulant therapyAntithrombotic therapy in cardiac embolism.Antithrombotic medication for cardioembolic stroke preventionDabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disordersNovel anticoagulants in atrial fibrillation stroke preventionRecent trends in cost-related medication nonadherence among stroke survivors in the United StatesNovel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis.Recent advances in oral anticoagulation for atrial fibrillation.Novel oral anticoagulants. Part II: direct thrombin inhibitors.Transforming oral anticoagulation by combining international normalized ratio (INR) self testing and online automated management.Oral anticoagulant-associated intracerebral hemorrhage.Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use.First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab.Synthesis and Biological Evaluation of Some New 2,5-Substituted 1-Ethyl-1H-benzoimidazole Fluorinated Derivatives as Direct Thrombin Inhibitors.A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation.Direct Thrombin Inhibitors
P2860
Q33888320-4CC624CF-66E4-4BD7-9F83-6AB04D221E60Q34362901-77117393-8D93-4145-AA71-2AB1A142F547Q35142419-3B436734-83DE-4097-B31D-F3C76DE05D06Q35187005-B304B49C-CE2F-475E-969D-9D838F5DF0C1Q35739671-E917EE2C-443D-460F-9F27-E71FE6884927Q36443814-2FCAFEC4-AE76-4291-A0C2-1070CBC137F2Q36916381-2DED19B1-3277-44BF-8A88-A283153F6E28Q37197199-D953BA83-2FF9-44AC-A87B-2AB45A53FA50Q37802084-031F58CD-FB75-4A20-949B-5B513AD7F4D5Q37810102-B5807C1E-E3B5-47B6-9B46-5E4DB92E8995Q37843744-0036CD58-C6E9-409B-A836-5E642EFFA039Q37900185-E7C3DDF6-5F27-46C1-8CAA-750B5543B919Q37990337-34A38947-724C-4BA6-9D64-D4DBF2333646Q38685055-1DC5249F-B886-4A03-890D-2E98CD339F37Q41138334-4B04610E-BC63-4EBF-8621-DFC3679F9CDBQ50501003-2BFCCBA5-3933-4586-82FE-B654E52B7426Q56003308-68D7A3CA-BBA9-4EA4-B293-8397968B0B9B
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Can we rely on RE-LY?
@en
Can we rely on RE-LY?
@nl
type
label
Can we rely on RE-LY?
@en
Can we rely on RE-LY?
@nl
prefLabel
Can we rely on RE-LY?
@en
Can we rely on RE-LY?
@nl
P356
P1476
Can we rely on RE-LY?
@en
P2093
Brian F Gage
P304
P356
10.1056/NEJME0906886
P407
P577
2009-08-30T00:00:00Z